WCM Investment Management LLC Has $12.23 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

WCM Investment Management LLC decreased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 127,150 shares of the medical equipment provider’s stock after selling 427 shares during the quarter. WCM Investment Management LLC’s holdings in Lantheus were worth $12,227,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Janus Henderson Group PLC increased its stake in Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock valued at $554,583,000 after acquiring an additional 2,610,118 shares during the period. Farallon Capital Management LLC grew its holdings in shares of Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after purchasing an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of Lantheus by 40.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after purchasing an additional 435,445 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $36,183,000. Finally, Assenagon Asset Management S.A. raised its stake in shares of Lantheus by 1,196.4% in the first quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider’s stock valued at $32,817,000 after purchasing an additional 310,301 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of the business’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.50% of the stock is owned by corporate insiders.

Lantheus Price Performance

Shares of LNTH stock opened at $79.62 on Thursday. The stock’s fifty day simple moving average is $83.51 and its 200 day simple moving average is $90.44. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89. The firm has a market cap of $5.51 billion, a price-to-earnings ratio of 22.62 and a beta of 0.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same quarter in the prior year, the firm posted $1.69 EPS. The firm’s revenue for the quarter was up .8% on a year-over-year basis. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on LNTH. B. Riley decreased their price target on shares of Lantheus from $122.00 to $109.00 and set a “buy” rating on the stock in a research note on Monday, June 23rd. Truist Financial reduced their price objective on shares of Lantheus from $127.00 to $117.00 and set a “buy” rating for the company in a report on Thursday, May 8th. Finally, Wall Street Zen raised shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus has a consensus rating of “Buy” and an average target price of $130.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.